DOCETAXEL-BASED PROLONGED-RELEASE CANCER TREATMENT DRUG

摘要

The present invention relates to the field of pharmacology and medicine, specifically to a new generation of anticancer drugs with the cytostatic action based on docetaxel. In the drug composition of the invention docetaxel is included in biodigestible stable nanoparticles. The nanoparticles comprise of docetaxel, PLGA, serum albumin and D-mannitol The developed drug is proposed to be manufactured as enterosoluble tablets, capsules granules, powder, or in any other peroral form.

主权项

1. A docetaxel-based prolonged-release cancer treatment drug, comprising in stable nanoparticles:
a) docetaxel, b) a polylactic-co-glycolic acid with a 50/50% monomer units molar ratio (PLGA 50/50) as a biodegradable polymer, c) serum albumin as a surface-active substance and d) D-mannitol as a cryoprotective agent, in the following component ratios, in mass percents:Docetaxel3.8-4.0PLGA 50/5038.3-38.7Serum albumin47.5-50.0D-mannitol 9.7-9.9.